Testing a new drug for multiple sclerosis in healthy people and MS patients
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old (or 18-60 if you have MS).
- You are in good health with no major medical problems.
- You are willing to have a lumbar puncture (spinal tap) to collect fluid for testing.
- You can attend all study visits and follow the study rules.
- You do not have a history of drug abuse, heavy alcohol use, or smoking within the last week.
- You have not donated blood or plasma in the last month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
This study tests whether a medicine that targets a specific brain inflammation marker (TSPO) can help in people with certain types of multiple sclerosis. It focuses on safety and whether the target can be measured and influenced during treatment.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.